The influence of physical activity on risk of cardiovascular disease in people who are obese but metabolically healthy

Shinje Moon¹*, Chang-Myung Oh²*, Moon-Ki Choi¹, Yoo-Kyung Park¹, Sukyung Chun², Minkyung Choi², Jae Myung Yu¹*, Hyung Joon Yoo¹*

¹ Division of Endocrinology and Metabolism, Hallym University College of Medicine, Chuncheon, South Korea, ² Division of Endocrinology and Metabolism, CHA Bundang Medical Center, School of Medicine CHA University, Pangyo, Seongnam, South Korea

☯ These authors contributed equally to this work.
* jaemyungyu@hallym.or.kr (JMY); hjoonyoo@gmail.com (HJY)

Abstract

The metabolic outcomes of metabolically healthy obesity (MHO) remain controversial. The aim of the present study was to determine the effect of physical activity on the cardiovascular disease (CVD) outcomes of MHO. The study included participants who were followed for 10 years and recruited from the Korean Genome and Epidemiology Study (KoGES), a population-based cohort study. Participants with previously recorded CVDs or cancer, or who had received steroids or anticoagulants at baseline were excluded. A total of 8144 participants (3,942 men and 4,202 women) fulfilled inclusion criteria. In a multivariate Cox regression model adjusted for age and sex, MHO participants were not at elevated risk of CVD compared with their metabolically healthy non-obese (MHNO) counterparts (HR, 1.28; 95% CI, 0.96–1.71), although both the non-obese (HR, 1.50; 95% CI, 1.19–1.90) and obese (HR, 1.85; 95% CI, 1.48–2.30) participants with metabolic abnormalities were at elevated risk. However, in the subgroup analysis by physical activity, physically inactive MHO participants had a significantly higher HR for CVD events compared to active MHNO participants (HR, 1.54; 95% CI, 1.03–2.30), while active MHO participants were not at elevated risk (HR, 1.15; 95% CI, 0.70–1.89). Physically inactive MHO participants had significantly increased risk of CVD compared to physically active MHNO participants whereas physically active MHO participants did not.

Introduction

The incidence of obesity is increasing and the worldwide prevalence of obesity more than doubled between 1980 and 2012 [1]. In Korea, the prevalence of obesity has increased over the past 10 years (20.6% to 24.6% in men, 16.2% to 17.3% in women from 2006 to 2015) [2]. These changes are particularly important given the known association between obesity with cardiovascular disease (CVD), diabetes, and death [3].

Intriguingly, obesity is not synonymous with metabolic disease, as people who are overweight or obese do not always have no metabolic dysfunction, especially cardio-metabolic
dysfunction. These populations have been called the metabolically healthy obesity (MHO) phenotype. The underlying mechanisms which cause MHO phenotype among obese people are multiple and complex. This phenotype is the result of complex interaction between genetic, environmental, and behavioral factors [4]. The absence of genetic traits associated with fat distribution, reduced visceral fat mass and ectopic fat accumulation in liver, muscle, and pancreatic beta cells, and low systemic inflammation all contribute to metabolically healthy obesity [4].

The diagnostic criteria for MHO is controversial, and therefore the prevalence of MHO is difficult to quantify and varies according to the definition used [5]. The prevalence of MHO has been reported to be 10–25% worldwide [6, 7], while the estimated prevalence among middle-age men in Korea is 24.2–28.5% [8]. A recent review article reported that the prevalence of MHO showed a large variation from 6% to 75% [9].

Although, by definition, people with MHO are metabolically ‘healthy’, the metabolic outcomes of MHO remain unclear. Regarding cardiovascular outcomes in this group of patients, Hamer et al. [10] observed 22,203 subjects without CVD for more than 7 years. This observational study revealed that MHO did not increase the risk for all-cause or cardiovascular mortality. Furthermore, MHO has little association with heart failure [11] and with coronary atherosclerosis [12]. On the contrary, several large observational studies reported that MHO is a significant risk factor for CVD. Ogorodnikova et al. [13] conducted a 12-year observational study and demonstrated patients with MHO had high risk of CVD compared to metabolically healthy normal weight individuals. Kramer et al. [14] reviewed 8 studies about all-cause mortality and cardiovascular events and concluded that obesity is an independent risk factor for CVD in patients with and without metabolic disorders.

These discrepancies suggest that MHO alone is not sufficient to predict metabolic outcome and patients with MHO likely represent a heterogeneous group. Therefore, it remains important to identify the key factors that determine healthy outcomes in MHO and to re-define metabolically healthy obesity.

In this study, we focused on physical activity (PA) as a key factor, since it is well known to influence obesity, and because physical inactivity contributes to the development of metabolic disorders such as heart disease, hypertension, and type 2 diabetes mellitus (T2DM) [15]. The World Health Organization (WHO) recommends that adults should perform at least 150 minutes of moderate-intensity aerobic physical activity (PA) or 75 minutes of vigorous-intensity aerobic PA throughout the week [16]. The U.S. Department of Health and Human Services also recommends at least 150 minutes of PA for major health benefits [17].

Many studies have reported that the amount of PA has inverse dose-response associations with coronary heart disease and CVD [18] and regular exercise improves insulin sensitivity and reduces glycosylated hemoglobin (HbA1c) levels in T2DM patients [19].

In the present study, patients with MHO were divided into four groups based on their level of PA, and we evaluated the risk of CVD in a Korean population-based cohort. The aim of the present study was to determine the effect of PA on CVD outcomes of MHO and to re-define the concept of “real” metabolic health.

**Materials and methods**

**Study population**

This was a prospective cohort study in which data were collected from two population-based cohorts from Ansan and Ansung, Korea, and was as part of the Korean Genome and Epidemiology Study (KoGES), a Korean government-funded epidemiological survey to investigate trends in chronic noncommunicable diseases and associated risk factors. A total of 10,038
participants were examined at baseline in 2001–2002 and the biennial follow-up examination is ongoing. The design of the cohort study and the demographics of participants have been described elsewhere [20].

The 10-year follow-up data are included in the present study. The following participants were excluded from the present study: those with incomplete data (demographic, anthropometric, or laboratory), those with a clinical history of CVD or cancer at baseline, and those who had received steroids or anticoagulants. The total number of eligible participants was 8,144.

Measurement

Height and body weight were measured to the nearest 0.1cm or 0.2kg, respectively. Blood pressure (BP) was measured in the sitting position after at least 5 minutes of rest. Blood samples were obtained after an overnight fast of at least 8 h, and biochemical assays including plasma glucose, total cholesterol (TC), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C) were measured using the ADVIA 1650 chemistry analyzer (Bayer HealthCare Ltd., Tarrytown, NY, USA). Hemoglobin A1c (HbA1c) level was measured using high-performance liquid chromatography (Variant II; BioRad Laboratories, Hercules, CA, USA).

The questionnaire included questions on sociodemographic information, lifestyle, personal and familial medical history, smoking status and alcohol consumption. The participants were classified as non-, ex-, and current drinkers and never-, ex-, and current smokers based on their response to lifetime alcohol consumption and smoking status on the questionnaire.

Definition

There is no consensus regarding the diagnosis of metabolically healthy obesity. In the present study, non-obese participants were defined as those with a body mass index (BMI) of 18–25 kg/m\(^2\) and obesity as a BMI of \(\geq 25\) kg/m\(^2\) according to Asia-Pacific BMI criteria, which are defined by the WHO Western Pacific Region [21]. Metabolic risk was based on an adaptation of the Adult Treatment Panel-III (ATP-III) definition of metabolic syndrome, and defined as two or more metabolic risk factors, including hypertension (a systolic blood pressure (BP) at least 130 mmHg and/or a diastolic BP at least 85 mmHg, or on antihypertensive treatment), impaired fasting glucose (fasting plasma glucose at least 100 mg/dL), triglycerides (TG) at least 150 mg/dL, and adverse high density lipoprotein (HDL) cholesterol (1.03 mmol/L in men and 1.30 mmol/L in women). The waist circumference (WC) criterion was not used because of its collinearity with BMI. According to these criteria, participants were categorized into one of four groups consisting of metabolically healthy non-obese (MHNO); metabolically healthy obese (MHO); metabolically unhealthy non-obese (MUNO); and metabolically unhealthy obese (MUO). All participants completed a structured questionnaire that included health-related questions concerning PA. The PA categories included a physically active group (at least 30 minutes per day of PA) and an insufficient group (fewer than 30 minutes per day of PA). Because there was no data about average minutes of PA per week in the baseline data, we were unable to use the WHO recommendation [16]. However, the intensity and average minutes per week of PA were investigated at the first follow-up survey and we conducted subgroup analysis of participants with the first follow-up data using the WHO definition which recommends at least 150 minutes of moderate-intensity aerobic PA or 75 minutes of vigorous-intensity aerobic PA throughout the week. CVD events were investigated with a structured questionnaire and defined as any of the following: myocardial infarction, coronary heart disease, congestive heart failure, cerebrovascular disease, or peripheral arterial disease.
Statistical analysis

All data are presented as the mean and standard deviation, or prevalence (%) and 95% confidence interval (CI). The independent sample t-test or one-way analysis of variance (ANOVA) was used to compare continuous variables and Pearson’s chi-square test was used to compare proportions according to metabolic health and obesity status. Cox proportional hazards regression models, unadjusted and adjusted, were constructed to evaluate the hazards ratio (HR) and 95% CI for CVD events in groups classified according to metabolic health and obesity status. Follow-up time was calculated as time from first anthropometric and clinical measures to date of CVD events or time from first anthropometric and clinical measurement to end of follow-up (December 31, 2012). Analyses were performed using SPSS version 21.0 software (IBM, Armonk, NY, USA). The significance levels were set at 0.05.

Ethics statement

The institutional review board of Bundang CHA Hospital (South Korea) approved the study protocol (IRB No. CHAMC 2016-08-017), and all participants volunteered and provided written informed consent prior to their enrollment. All participants’ records were anonymized before being accessed by the authors.

Results

Baseline characteristics

Data from 8,144 participants (3,942 men and 4,202 women) were assessed. The anthropometric, clinical, and biochemical characteristics of the participants classified by obesity and metabolic health status are summarized in Table 1.

Among the included participants, 15.5% exhibited the MHO phenotype. Compared to MHNO participants, those with the MHO phenotype tended to be female and have a high BMI (both p < 0.01). However, other characteristics such as mean age, alcohol drinking, smoking status, and metabolic parameters did not differ significantly between the two groups. Participants with MUNO and MUO phenotype were more likely to be older and to have higher BP, TG, and HbA1c levels, lower levels of HDL-C, and a higher prevalence of prehypertension and prediabetes than those with MHNO and MHO phenotypes.

Association between CVD events and metabolically healthy-obesity phenotype

A total of 568 CVD events were reported during the 10 years. Kaplan-Meier survival curves revealed a significantly higher rate of CVD events in participants with the MUNO and MUO phenotypes than in those with the MHNO phenotype (MUNO vs. MHNO, p < 0.001; MUO vs. MHNO, p < 0.001). However, there was no significant difference between participants with the MHNO and MHO phenotype (p = 0.272; Fig 1).

In a multivariate Cox regression model adjusted for age and gender, MHO participants were not at elevated risk of CVD compared with their MHNO counterparts (HR, 1.28; 95% CI, 0.96–1.71), although both the non-obese (HR, 1.50; 95% CI, 1.19–1.90) and obese (HR, 1.85; 95% CI, 1.48–2.30) participants with metabolic abnormalities were at elevated risk (Table 2). Similar results were seen after adjustment for age, gender, and other covariates such as alcohol drinking, smoking, PA, and medications.
Effects of physical activity on CVD events by obesity and metabolic health status

We further performed a subgroup analysis by PA status. Participants with the MUNO and MUO phenotype were more likely to be physically inactive than those with the MHNO and MHO phenotype (Table 1). The adjusted HRs of CVD events by PA, obesity, and metabolic health status are shown in Table 3.

In a multivariate Cox regression model adjusted for age and gender, the HR for CVD events slightly increased from 1.89 (95% CI, 1.30–2.74) in active participants with MUO reaching 2.05 (95% CI, 1.48–2.85) in inactive counterparts with MUO compared to physically active MUNO participants. A similar increase of HR was found in those with MUNO as well (HR, 1.60; 95% CI, 1.08–2.36 in active participants; HR, 1.64; 95% CI, 1.16–2.32 in inactive participants). Compared to active MHNO participants, physically inactive MHO participants had a significantly higher HR for CVD events (HR, 1.54; 95% CI, 1.03–2.30), while active participants were not at elevated risk of CVD (HR, 1.15; 95% CI, 0.70–1.89). The subgroup analysis with the first follow-up data for PA showed comparable results (S1 Table). In addition, we

| Table 1. Characteristics of subjects according to obesity and metabolic health status. |
|-----------------------------------------------|---------------|---------------|----------------|---------------|----------------|
|                                              | MHNO (N = 2929) | MHO (N = 1262) | MUNO (N = 1743) | MUO (N = 2210) | P-value       |
| Men, N                                       | 1501 (51.2%)   | 560 (44.4%)    | 875 (50.2%)     | 1006 (45.5%)   | <0.001        |
| Age, years                                   | 48 (43–58)     | 48 (43–56)     | 55 (46–63)      | 52 (45–60)     | <0.001        |
| Alcohol, N                                   |                |               |                |               | <0.001        |
| Never drinker                                | 1265 (43.2%)   | 528 (41.8%)    | 819 (47.0%)     | 1102 (49.9%)   |               |
| Ex-drinker                                   | 167 (5.7%)     | 74 (5.9%)      | 116 (6.7%)      | 147 (6.7%)     |               |
| Current drinker                              | 1497 (51.1%)   | 660 (52.3%)    | 808 (46.4%)     | 961 (43.5%)    |               |
| Physical activity*, N                        | 1139 (38.9%)   | 504 (39.9%)    | 616 (35.3%)     | 760 (34.4%)    | 0.001         |
| BMI, Kg/m²                                    | 22.5 (21.0–23.7) | 26.6 (25.7–28.0) | 23.3 (22.0–24.2) | 27.0 (26.0–28.7) | <0.001        |
| Systolic BP, mmHg                            | 112 (104–121)  | 114 (106–122)  | 127 (114–139)   | 128 (117–140)  | <0.001        |
| Diastolic BP, mmHg                           | 75 (69–81)     | 78 (71–83)     | 84 (75–90)      | 86 (78–92)     | <0.001        |
| Total cholesterol, mg/dL                    | 182 (161–205)  | 193 (169–217)  | 188 (165–213)   | 197 (175–222)  | <0.001        |
| HDL-C, mg/dL                                 | 48.0 (42.0–55.0) | 46.0 (41.0–52.0) | 40.0 (35.0–45.5) | 39.0 (35.0–44.0) | <0.001        |
| Triglycerides, mg/dL                         | 104 (83–128)   | 114 (92–138)   | 180 (147–235)   | 189 (153–256)  | <0.001        |
| HbA1c, %                                     | 5.5 (5.3–5.7)  | 5.5 (5.3–5.8)  | 5.7 (5.4–6.0)   | 5.8 (5.5–6.2)  | <0.001        |
| Metabolic state, N                           |                |               |                |               |               |
| Hyperglycemia                                | 93 (3.2%)      | 47 (3.7%)      | 479 (27.5%)     | 687 (31.1%)    | <0.001        |
| Low HDL-C                                    | 876 (29.9%)    | 447 (35.4%)    | 1313 (75.3%)    | 1783 (80.7%)   | <0.001        |
| High TG                                      | 247 (8.4%)     | 163 (12.9%)    | 1290 (74.0%)    | 1700 (76.9%)   | <0.001        |
| CVD events†, N                               | 135 (4.6%)     | 70 (5.5%)      | 155 (8.9%)      | 208 (9.4%)     | <0.001        |
| Follow up time, years                        | 8.3 (8.2–8.4)  | 8.5 (8.3–8.6)  | 8.2 (8.0–8.3)   | 8.1 (8.0–8.3)  | 0.002         |

Abbreviations: MHNO, metabolically healthy nonobese; MHO, metabolically healthy obese; MUNO, metabolically unhealthy nonobese; and MUO, metabolically unhealthy obese; N; number, BP, blood pressure; HDL-C, high density lipoprotein cholesterol, CVD, cardiovascular diseases.

* Participants who engaged in physical activity for at least 30 minutes per day
† Participants who had either myocardial infarction, coronary heart disease, congestive heart failure, cerebrovascular disease or peripheral arterial disease

Data were presented as the means (95% CI) or numbers (%)
conducted further analysis with MHNO and MHO participants by presence of metabolic abnormality and found that MHO with one metabolic abnormality and inactive PA increased the risk of CVD event (HR; 1.786; 95% CI, 1.047–2.987) whereas those with no metabolic abnormality or active PA did not (Table 4).

Discussion

In this study, we performed a long-term follow-up study of Korean patients and analyzed the risk for CVD in patients with MHO phenotype. The MUO and MUNO groups had significantly higher risk for CVD than the MHNO group. Although the present study failed to find significant results between the MHO and MHNO groups, the subgroup analysis by PA status showed that the MHO group with insufficient PA had worse prognosis than the MHNO group

Table 2. Hazard ratios for CVD events according to obesity and metabolic health status.

|                | Model1 |                | Model2 |                |
|----------------|--------|----------------|--------|----------------|
|                | HR (95%CI) | P | HR (95%CI) | P |
| MHNO           | 1 (Reference) |   | 1 (Reference) |   |
| MHO            | 1.280 (0.957–1.710) | 0.096 | 1.288 (0.963–1.723) | 0.088 |
| MUNO           | 1.503 (1.190–1.899) | 0.001 | 1.358 (1.071–1.724) | 0.012 |
| MUO            | 1.847 (1.484–2.299) | <0.001 | 1.596 (1.268–2.007) | <0.001 |

Abbreviations: MHNO, metabolically healthy nonobese; MHO, metabolically healthy obese; MUNO, metabolically unhealthy nonobese; and MUO, metabolically unhealthy obese; HR, hazard ratios; CI, confidential interval.

Model 1 was adjusted for age and gender.

Model 2 was adjusted for the variables in Model 1, plus alcohol drinking, smoking, physical activity and medication of hypertension, diabetes mellitus and dyslipidemia.

https://doi.org/10.1371/journal.pone.0185127.t002
with sufficient PA. Interestingly, despite being obese, the prognosis of physically active individuals with MHO did not differ significantly from that of MHNO individuals.

These results show that metabolically healthy obese populations are not homogenous. This heterogeneity of ‘obesity’ is due to a limitation in the classification of obesity by BMI. First, obesity is defined as excess body fat mass, but BMI does not accurately reflect body fat mass \[22\], since bodyweight cannot distinguish between excess fat and excess muscle or bone mass. Second, extra fat is not always bad. Adipose tissue is a complex organ composed of white, beige, and brown fat. The beige/brown fat has many beneficial effects on metabolism \[23\]. Furthermore, the metabolic effects of fat differ according to its location. For example, excess visceral fat mass has deleterious effects on metabolism and is an independent risk factor of metabolic syndrome, type 2 diabetes, CVD and cancer \[24, 25\], whereas subcutaneous fat has beneficial effects on metabolism \[26\]. In one animal study, subcutaneous fat transplantation improved metabolic dysfunction in an obese mouse model \[27\].

In order to overcome this limitation of obesity classification according to BMI, many studies tried to evaluate obesity using other body index parameters such as waist circumference, waist hip ratio or waist height ratio \[28, 29\], and reported that these other indexes explained

### Table 3. Hazard ratios for CVD events according to obesity, metabolic health status and physical activity.

|                  | Model1                  |      | Model2                  |      |
|------------------|-------------------------|------|-------------------------|------|
|                  | HR (95% CI)             | P    | HR (95% CI)             | P    |
| MHNO with active PA | 1 (Reference)           |      | 1 (Reference)           |      |
| MHNO with inactive PA | 1.129 (0.794–1.607)     | 0.498| 1.112 (0.781–1.582)     | 0.557|
| MHO with active PA  | 1.147 (0.697–1.886)     | 0.590| 1.147 (0.697–1.888)     | 0.590|
| MHO with inactive PA | 1.536 (1.026–2.298)     | 0.037| 1.524 (1.018–2.281)     | 0.041|
| MUNO with active PA | 1.598 (1.081–2.361)     | 0.019| 1.438 (0.970–2.133)     | 0.071|
| MUNO with inactive PA | 1.640 (1.160–2.320)     | 0.005| 1.467 (1.034–2.081)     | 0.032|
| MUO with active PA  | 1.890 (1.304–2.741)     | 0.001| 1.608 (1.101–2.349)     | 0.014|
| MUO with inactive PA | 2.051 (1.475–2.853)     | <0.001| 1.767 (1.262–2.474)     | 0.001|

Abbreviations: MHNO, metabolically healthy nonobese; MHO, metabolically healthy obese; MUNO, metabolically unhealthy nonobese; and MUO, metabolically unhealthy obese; PA, physical activity; HR, hazard ratios; CI, confidential interval.

Model 1 was adjusted for age and gender.

Model 2 was adjusted for the variables in Model 1, plus drinking, smoking, physical activity and medication of hypertension, diabetes mellitus and dyslipidemia.

https://doi.org/10.1371/journal.pone.0185127.t003

### Table 4. Age and sex adjusted hazard ratios for CVD events according to obesity, metabolic health status and physical activity based on strict definition.

|                  | HR (95% CI)             | P    |
|------------------|-------------------------|------|
| MHNO with active PA (no metabolic abnormality) | 1 (Reference)           |      |
| MHNO with inactive PA (no metabolic abnormality) | 1.115 (0.653–1.906)     | 0.690|
| MHO with active PA (no metabolic abnormality)  | 1.256 (0.536–2.945)     | 0.599|
| MHO with inactive PA (no metabolic abnormality) | 0.950 (0.424–2.127)     | 0.900|
| MHO with active PA (one metabolic abnormality) | 1.111 (0.584–2.113)     | 0.748|
| MHO with inactive PA (one metabolic abnormality) | 1.768 (1.047–2.987)     | 0.033|

Abbreviations: MHNO, metabolically healthy nonobese; MHO, metabolically healthy obese; MUNO, metabolically unhealthy nonobese; and MUO, metabolically unhealthy obese; PA, physical activity; HR, hazard ratios; CI, confidential interval.

https://doi.org/10.1371/journal.pone.0185127.t004
obesity related metabolic disorders than BMI. However, these indexes are still an indirect reflection of excess fat mass, and therefore additional clinical data accumulation is required to replace BMI. To measure regional body fat composition accurately, we can measure body composition or fat mass using computed tomography (CT), magnetic resonance imaging, DXA and PET-CT [30, 31]. Unfortunately, these methods are expensive, and have limited availability and accessibility for long-term follow up in a large-scale cohort study.

Therefore, the degree of PA is an easily measured and inexpensive alternative to the methods described above which is useful in predicting the CVD risk of obesity and a suitable alternative to overcome the limitation of BMI. In our data, the degree of PA acts an independent prognostic factor on the CVD outcome even in the same metabolic comorbidity. In fact, PA has been reported as a protective factor against the development of CVD in many clinical studies [18], Jian Li et al. [32] reported that PA reduced the overall risk of CVD among men and women by 20–30% and 10–20% percent, respectively. PA is an independent regulator of body fat percent and body composition [33], and is associated with the activity of brown adipose tissue [34].

In our study cohort, physically active individuals comprised 39.9% of the MHO group (Table 1). More than half of the participants in the MHO group were physically inactive. When assessing the CVD outcome of the overall MHO group, this ratio resulted in an increased, but not statistically significant risk (HR 1.280, p > 0.05). Therefore, PA can provide a convincing explanation for the discrepant results of previous longitudinal studies about the risk of developing CVD in MHO [35–38]. Taken together, these findings demonstrate that the degree of PA should be considered alongside other determining factors such as obesity and metabolic comorbidity when predicting cardiovascular risk.

The main strength of this study is that this was a long-term population-based cohort study (10-year follow up) from a single ethnic group. This study also has several limitations. First, we were unable to analyze fat distribution or use other demographic indexes associated with obesity such as waist circumference. Therefore, we did not account for all of the important factors associated with CVD risk. Second, since we could not assess mortality data, we may have missed fatal CVD events. In conclusion, we analyzed the CVD outcomes according to obesity and metabolic health status in a Korean population. Physically inactive MHO participants had significantly increased risk of CVD compared to physically active MHNO participants, whereas physically active MHO participants did not. Further studies are required to re-define MHO in view of PA status in order to better characterize ‘real’ metabolically healthy obesity.

Supporting information

S1 Table. Age and sex adjusted hazard ratios for CVD events according to obesity, metabolic health status and physical activity based on the WHO definition. Abbreviations: MHNO, metabolically healthy nonobese; MHO, metabolically healthy obese; MUNO, metabolically unhealthy nonobese; and MUO, metabolically unhealthy obese; PA, physical activity; HR, hazard ratios; CI, confidential interval.

(PDF)

Acknowledgments

Data in this study were from the Korean Genome and Epidemiology Study (KoGES; 4851–302). National Research Institute of Health, Centers for Disease Control and Prevention, Ministry for Health and Welfare, Republic of Korea. This research was supported by the grant (C.
M.O., 2016S-1) from the Korean Diabetes Association, Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2016R1A6A3A04010466 to C.M.O).

Author Contributions

**Conceptualization:** Shinje Moon, Chang-Myung Oh, Moon-Ki Choi, Yoo-Kyung Park, Jae Myung Yu, Hyung Joon Yoo.

**Data curation:** Shinje Moon, Chang-Myung Oh, Yoo-Kyung Park, Sukyung Chun, Minkyung Choi.

**Formal analysis:** Shinje Moon, Chang-Myung Oh, Yoo-Kyung Park, Sukyung Chun, Minkyung Choi.

**Funding acquisition:** Chang-Myung Oh.

**Investigation:** Shinje Moon, Chang-Myung Oh, Hyung Joon Yoo.

**Methodology:** Shinje Moon, Chang-Myung Oh, Moon-Ki Choi, Sukyung Chun, Jae Myung Yu, Hyung Joon Yoo.

**Project administration:** Chang-Myung Oh, Jae Myung Yu, Hyung Joon Yoo.

**Software:** Shinje Moon, Yoo-Kyung Park, Sukyung Chun.

**Supervision:** Moon-Ki Choi, Jae Myung Yu.

**Writing – original draft:** Shinje Moon, Chang-Myung Oh.

**Writing – review & editing:** Jae Myung Yu, Hyung Joon Yoo.

References

1. World Health Organization. World health statistics 2012. World Health Organization: Geneva 2012.
2. Korean Society for the Study of Obesity (KSSO): 2016 obesity fact sheet. Available from: http://www.kosso.or.kr/file/factsheet_1006new6_web.pdf.
3. Solomon CG, Manson J. Obesity and mortality: a review of the epidemiologic data. The American journal of clinical nutrition. 1997; 66:1044S–50S. PMID: 9322585
4. Seo MH, Rhee E-J. Metabolic and cardiovascular implications of a metabolically healthy obesity phenotype. Endocrinol Metab (Seoul) 2014; 29: 427–434.
5. Velho S, Paccaud F, Waerger G, Vollenweider P, Marques-Vidal P. Metabolically healthy obesity: different prevalences using different criteria. Eur J Clin Nutr 2010; 64:1043–51. https://doi.org/10.1038/ejcn.2010.114 PMID: 20628408
6. Blüher M. The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. Curr Opin Lipidol 2010; 21:38–43. https://doi.org/10.1097/MOL.0b013e3283346ccc PMID: 19915462
7. Karelis AD. Obesity: to be obese—does it matter if you are metabolically healthy? Nat Rev Endocrinol 2011; 7:699–700. https://doi.org/10.1038/nrendo.2011.181 PMID: 22009160
8. Yoo HK, Choi EY, Park EW, Cheong Y-S, Bae RA. Comparison of metabolic characteristics of metabolically healthy but obese (MHO) middle-aged men according to different criteria. Korean J Fam Med 2013; 34:19–26. https://doi.org/10.4082/kjfmm.2013.34.1.19 PMID: 23372902
9. Rey-López J, Rezende L, Pastor-Valero M, Tess B. The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used. Obes Rev 2014; 15:781–90. https://doi.org/10.1111/obr.12198 PMID: 25040597
10. Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab 2012; 97:2482–8. https://doi.org/10.1210/jc.2011-3475 PMID: 22508708
11. Voulgaris C, Tentolouris N, Dilaveris P, Tousoulis D, Katsilambros N, Stefanadis C. Increased heart failure risk in normal-weight people with metabolic syndrome compared with metabolically healthy obese
individuals. J Am Coll Cardiol 2011; 58:1343–50. https://doi.org/10.1016/j.jacc.2011.04.047 PMID: 21920263

12. Morkedal B, Vatten LJ, Romundstad PR, Laugsand LE, Janszky I. Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals. J Am Coll Cardiol 2014; 63:1071–8. https://doi.org/10.1016/j.jacc.2013.11.035 PMID: 24345592

13. Ogorodnikova AD, Kim M, McGinn AP, Muntner P, Khan U, Wildman RP. Incident cardiovascular disease events in metabolically benign obese individuals. Obesity. 2012; 20:651–9. https://doi.org/10.1038/oby.2011.243 PMID: 21799477

14. Kramer CK, Zimman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis. Ann Intern Med 2013; 159:758–69. https://doi.org/10.7326/0003-4819-159-11-201312030-00008 PMID: 24297192

15. Strasser B. Physical activity in obesity and metabolic syndrome. Ann N Y Acad Sci 2013; 1281:141–59. https://doi.org/10.1111/j.1749-6632.2012.06785.x PMID: 23167451

16. World Health Organization. Global recommendations on physical activity for health. World Health Organization: Geneva 2010.

17. Tucker JM, Welk GJ, Beyler NK. Physical activity in US adults: compliance with the physical activity guidelines for Americans. Am J Prev Med. 2011; 40: 454–461. https://doi.org/10.1016/j.amepre.2010.12.016 PMID: 21406280

18. Shiruma EJ, Lee I-M. Physical activity and cardiovascular health. Circulation. 2010; 122:743–52. https://doi.org/10.1161/CIRCULATIONAHA.109.914721 PMID: 20739039

19. Way KL, Hackett DA, Baker MK, Johnson NA. The effect of regular exercise on insulin sensitivity in type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab J 2016; 40:253–71. https://doi.org/10.1093/dmj/dmv049 PMID: 27535644

20. Choi SH, Kim TH, Lim S, Park KS, Jang HC, Cho NH. Hemoglobin A1c as a diagnostic tool for diabetes screening and new-onset diabetes prediction. Diabetes care. 2011; 34:944–9. https://doi.org/10.2337/dc10-0643 PMID: 21355372

21. Lin W-Y, Lee L-T, Chen C-Y, Lo H, Hsia H-H, Liu I-L, et al. Optimal cut-off values for obesity: using simple anthropometric indices to predict cardiovascular risk factors in Taiwan. Int J Obes Relat Metab Disord 2002; 26:1232–8. https://doi.org/10.1038/sj.ijo.0802040 PMID: 12187401

22. Rahman M, Berenson AB. Accuracy of current body mass index obesity classification for white, black and Hispanic reproductive-age women. Obstet Gynecol 2010; 115:982. https://doi.org/10.1097/AOG.0b013e3181da4923 PMID: 20410772

23. Harms M, Seale P. Brown and beige fat: development, function and therapeutic potential. Nat Med 2013; 19:1252–63. https://doi.org/10.1038/nm.3361 PMID: 24100998

24. Gastaldelli A, Miyazaki Y, Pettiti M, Matsuda M, Mahankali S, Santini E, et al. Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab 2002; 87:5098–103. https://doi.org/10.1210/jc.2002-020696 PMID: 12414878

25. Donohoe CL, Doyle SL, Reynolds JV. Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr 2011; 3:12. https://doi.org/10.1186/1758-5996-3-12 PMID: 21666633

26. Shimizu I, Yoshida Y, Minamino T. Maintenance of Subcutaneous Fat Homeostasis Improves Systemic Metabolic Dysfunction in Obesity. Diabetes. 2015; 64:3984–6. https://doi.org/10.2337/db15-0013 PMID: 26604172

27. Tran TT, Yamamoto Y, Gesta S, Kahn CR. Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab 2008; 7:410–20. https://doi.org/10.1016/j.cmet.2008.04.004 PMID: 18460332

28. Bener A, Youssafzai MT, Darwish S, Al-Hamaq AO, Nasralla EA, Abdul-Ghani M. Obesity index that better predict metabolic syndrome: body mass index, waist circumference, waist hip ratio, or waist height ratio. J Obes 2013; 2013. https://doi.org/10.1155/2013/269038 PMID: 24000319

29. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 2004; 79:379–84. PMID: 14995210

30. Wells J, Fewtrell M. Measuring body composition. Arch Dis Child 2006; 91:612–7. https://doi.org/10.1136/adc.2005.085522 PMID: 16790722

31. Cronin CG, Prakash P, Daniels GH, Boland GW, Kalra MK, Halpern EF, et al. Brown fat at PET/CT: correlation with patient characteristics. Radiology. 2012; 263:336–42. https://doi.org/10.1148/radiol.12110683 PMID: 22623697

32. Li J, Siegrist J. Physical activity and risk of cardiovascular disease—a meta-analysis of prospective cohort studies. Int J Environ Res Public Health 2012; 9:391–407. https://doi.org/10.3390/ijerph1202391 PMID: 22470299
33. Zanovec M, Lakkakula AP, Johnson LG, Turri G. Physical activity is associated with percent body fat and body composition but not body mass index in white and black college students. Int J Exerc Sci 2009; 2:175. PMID: 27182315

34. Dinas PC, Nikaki A, Jamurtas AZ, Prassopoulos V, Ethymiadou R, Koutedakis Y, et al. Association between habitual physical activity and brown adipose tissue activity in individuals undergoing PET-CT scan. Clin Endocrinol (Oxf) 2015; 82:147–54.

35. Årnlov J, Ingelsson E, Sundström J, Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation. 2010; 121:230−6. https://doi.org/10.1161/CIRCULATIONAHA.109.887521 PMID: 20038741

36. Hinnouho G-M, Czernichow S, Dugravot A, Batty GD, Kivimaki M, Singh-Manoux A. Metabolically healthy obesity and risk of mortality. Diabetes care. 2013; 36:2294–300. https://doi.org/10.2337/dc12-1654 PMID: 23637352

37. Ortega FB, Lee D-c, Katzmarzyk PT, Ruiz JR, Sui X, Church TS, et al. The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness. Eur Heart J 2013; 34:389–97. https://doi.org/10.1093/eurheartj/ehs174 PMID: 22947612

38. Merkedal B, Vatten LJ, Romundstad PR, Laugsand LE, Janszky I. Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trøndelag Health Study), Norway. J Am Coll Cardiol 2014; 63:1071–8. https://doi.org/10.1016/j.jacc.2013.11.035 PMID: 24345592